Suit to block approval of generic Copaxone dismissed

WASHINGTON — Teva Pharmaceutical on Wednesday was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis drug, 10 days before the patent on the medication expires, according to a Bloomberg report published Thursday morning. 

The court ruled that the suit had been filed prematurely and could be refiled at a later date, according to the report. 

According to the report, Teva is appealing a 2013 dismissal of Teva’s suits against Mylan and Sandoz for infringing patents covering Copaxone. That case is pending before the Supreme Court.